Old Web
English
Sign In
Acemap
>
authorDetail
>
Suparna Wedam
Suparna Wedam
Food and Drug Administration
Breast cancer
Internal medicine
Medicine
Proportional hazards model
Fulvestrant
2
Papers
0
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
U.S. FDA Drug Approvals for Breast Cancer - A Decade in Review.
2021
Clinical Cancer Research
Shaily Arora
Preeti Narayan
Christy Osgood
Suparna Wedam
Tatiana M. Prowell
Jennifer J Gao
Mirat Shah
Danielle Krol
Sakar Wahby
Melanie Royce
Soma Ghosh
Reena Philip
Gwynn Ison
Tara Berman
Christina Brus
Erik Bloomquist
Mallorie H. Fiero
Shenghui Tang
Richard Pazdur
Amna Ibrahim
Laleh Amiri-Kordestani
Julia A. Beaver
Show All
Source
Cite
Save
Citations (0)
Overall Survival in Patients with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer Treated with a CDK 4/6 Inhibitor Plus Fulvestrant: A U.S. Food and Drug Administration Pooled Analysis
2021
Social Science Research Network
Jennifer J. Gao
Joyce Cheng
Tatiana M. Prowell
Erik Bloomquist
Shenghui Tang
Suparna Wedam
Melanie E Royce
Danielle Krol
Christy Osgood
Gwynn Ison
Rajeshwari Sridhara
Richard Pazdur
Julia A. Beaver
Laleh Amiri-Kordestani
Show All
Source
Cite
Save
Citations (0)
1